On today’s solo episode, I am sharing updates in triple negative breast cancer (TNBC). TNBC accounts for about 10-15% of all breast cancer and is an aggressive subtype. I talk about general treatment for TNBC, updates to early stage breast cancer including addition of immunotherapy with pembrolizumab (Keytruda) and use of PARP inhibitors (olaparib- Lynparza). I break down what we do for residual disease after neoadjuvant chemotherapy and surgery. After discussion of early stage breast cancer, we switch to talking about metastatic breast cancer and addition of immunotherapy and sacituzumab govitecan (Trodelvy). Finally, I end with a discussion of a really incredible ongoing vaccine trial.